Skip to main content
Boehringer agrees to delay biosimilar Humira launch

Boehringer Ingelheim settled a patent dispute with AbbVie over a biosimilar version of AbbVie's Humira, or adalimumab, with Boehringer agreeing to delay US introduction until July 2023. Amgen, Fresenius Kabi, Mylan, Samsung Bioepis, Pfizer and Novartis unit Sandoz have reached similar patent settlements with AbbVie.

Full Story: